These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17517840)

  • 1. Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography.
    Li Y; Nguyen MH; Derendorf H; Cheng S; Clancy CJ
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2985-7. PubMed ID: 17517840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments.
    Clancy CJ; Huang H; Cheng S; Derendorf H; Nguyen MH
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2569-72. PubMed ID: 16801448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel.
    Samra Z; Yardeni M; Peled N; Bishara J
    Eur J Clin Microbiol Infect Dis; 2005 Sep; 24(9):592-5. PubMed ID: 16172856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fluconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata.
    Posteraro B; Martucci R; La Sorda M; Fiori B; Sanglard D; De Carolis E; Florio AR; Fadda G; Sanguinetti M
    J Clin Microbiol; 2009 Jun; 47(6):1927-30. PubMed ID: 19403774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.
    Quindós G; Sánchez-Vargas LO; Villar-Vidal M; Eraso E; Alkorta M; Hernández-Almaraz JL
    Int J Antimicrob Agents; 2008 Mar; 31(3):266-71. PubMed ID: 18054468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic modelling and in vitro simulation of dynamic voriconazole-Candida interactions.
    Li Y; Nguyen MH; Schmidt S; Zhong L; Derendorf H; Clancy CJ
    Int J Antimicrob Agents; 2009 Sep; 34(3):240-5. PubMed ID: 19339162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of posaconazole and voriconazole in vitro killing against Candida krusei.
    Cantón E; Pemán J; Valentín A; Bosch M; Espinel-Ingroff A; Gobernado M
    Diagn Microbiol Infect Dis; 2008 Oct; 62(2):177-81. PubMed ID: 18691842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media.
    Pfaller MA; Messer SA; Houston A; Mills K; Bolmstrom A; Jones RN
    J Clin Microbiol; 2000 Oct; 38(10):3715-7. PubMed ID: 11015389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of voriconazole against Candida species isolated in Taiwan.
    Yang YL; Cheng HH; Lo HJ
    Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.
    Cuenca-Estrella M; Gomez-Lopez A; Cuesta I; Zaragoza O; Mellado E; Rodriguez-Tudela JL;
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1794-7. PubMed ID: 21282420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
    Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients.
    Burn AK; Fothergill AW; Kirkpatrick WR; Coco BJ; Patterson TF; McCarthy DI; Rinaldi MG; Redding SW
    J Clin Microbiol; 2004 Dec; 42(12):5846-8. PubMed ID: 15583322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postantifungal effect of the combination of caspofungin with voriconazole and amphotericin B against clinical Candida krusei isolates.
    Oz Y; Kiremitci A; Dag I; Metintas S; Kiraz N
    Med Mycol; 2013 Jan; 51(1):60-5. PubMed ID: 22746405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Ng KP; Colombo A; Finquelievich J; Barnes R; Wadula J;
    J Clin Microbiol; 2008 Mar; 46(3):842-9. PubMed ID: 18199791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential fungicidal effect of voriconazole against Candida spp.
    Rubio MC; de Ocáriz IR; Gil J; Benito R; Rezusta A
    Int J Antimicrob Agents; 2005 Mar; 25(3):264-7. PubMed ID: 15737524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of Candida albicans fungemia during voriconazole therapy.
    Mohammedi I; Thiebaut A; Piens MA; Argaud L; Martin O; Robert D
    J Infect; 2005 Oct; 51(3):e83-4. PubMed ID: 16230209
    [No Abstract]   [Full Text] [Related]  

  • 18. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.
    Magill SS; Shields C; Sears CL; Choti M; Merz WG
    J Clin Microbiol; 2006 Feb; 44(2):529-35. PubMed ID: 16455909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole.
    Pfaller MA; Diekema DJ; Boyken L; Messer SA; Tendolkar S; Hollis RJ
    J Clin Microbiol; 2003 May; 41(5):1875-80. PubMed ID: 12734220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies.
    Scorneaux B; Angulo D; Borroto-Esoda K; Ghannoum M; Peel M; Wring S
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.